Precision BioSciences to present late-breaking AASLD 2026 data on PBGENE-HBV study
Bitget2026/10/08 11:04Precision BioSciences secured a late-breaking oral slot at AASLD’s Liver Meeting 2026 for its PBGENE-HBV clinical program. Results have not been presented yet; data are scheduled for Nov. 8, 2026, in Denver. The abstract reports durable loss of a key viral RNA signal in both HBeAg-positive and HBeAg-negative patients. The readout supports a potential path toward a functional cure strategy, a key de-risking milestone for the program. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610080701BIZWIRE_USPR_____20261008_BW153055) on October 08, 2026, and is solely responsible for the information contained therein.
- Precision BioSciences secured a late-breaking oral slot at AASLD’s Liver Meeting 2026 for its PBGENE-HBV clinical program.
- Results have not been presented yet; data are scheduled for Nov. 8, 2026, in Denver.
- The abstract reports durable loss of a key viral RNA signal in both HBeAg-positive and HBeAg-negative patients.
- The readout supports a potential path toward a functional cure strategy, a key de-risking milestone for the program.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
